Aptabio Therapeutics (XKRX:293780) COGS-to-Revenue : 0.94 (As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is Aptabio Therapeutics COGS-to-Revenue?

Aptabio Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2025 was ₩359 Mil. Its Revenue for the three months ended in Mar. 2025 was ₩383 Mil.

Aptabio Therapeutics's COGS to Revenue for the three months ended in Mar. 2025 was 0.94.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Aptabio Therapeutics's Gross Margin % for the three months ended in Mar. 2025 was 6.12%.

Aptabio Therapeutics COGS-to-Revenue Historical Data

The historical data trend for Aptabio Therapeutics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptabio Therapeutics COGS-to-Revenue Chart

Aptabio Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.76

0.91

Aptabio Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
COGS-to-Revenue	Get a 7-Day Free Trial															0.88	0.96	0.91	0.88	0.94

Aptabio Therapeutics COGS-to-Revenue Calculation

Aptabio Therapeutics's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	3074.364	/	3360.98
	=	0.91

Aptabio Therapeutics's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	359.276	/	382.701
	=	0.94

Aptabio Therapeutics (XKRX:293780) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Aptabio Therapeutics's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	359.276 / 382.701
	=	6.12 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Aptabio Therapeutics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Aptabio Therapeutics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Aptabio Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aptabio Therapeutics Inc (XKRX:293780) » Definitions » COGS-to-Revenue

Traded in Other Exchanges

N/A

Address

13, Heungdeok 1-ro, Giheung-gu, Tower 504, Gyeonggi-do, Yongin-Si, KOR, 16954

Website

http://www.aptabio.com

Aptabio Therapeutics Inc is a South Korean pharmaceutical company involved in discovery and development of selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs. The product portfolio of the company include Lipofector-Q, Plusfector, Lipofector-EXT, Lipofector-2000, Lipofector-EZ and Lipofector-pMAX.

Aptabio Therapeutics Headlines

No Headlines